BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Leiva O, Connors JM, Al-Samkari H. Impact of Tumor Genomic Mutations on Thrombotic Risk in Cancer Patients. Cancers (Basel) 2020;12:E1958. [PMID: 32707653 DOI: 10.3390/cancers12071958] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Ruiz-artacho P, Lecumberri R, Trujillo-santos J, Font C, López-núñez JJ, Peris ML, Díaz Pedroche C, Lobo JL, López Jiménez L, López Reyes R, Jara Palomares L, Pedrajas JM, Mahé I, Monreal M; The RIETE Investigators. Cancer Histology and Natural History of Patients with Lung Cancer and Venous Thromboembolism. Cancers 2022;14:4127. [DOI: 10.3390/cancers14174127] [Reference Citation Analysis]
2 Mantha S, Rak J. Cancer genetic alterations and risk of venous thromboembolism. Thrombosis Research 2022;213:S29-34. [DOI: 10.1016/j.thromres.2021.12.008] [Reference Citation Analysis]
3 West MT, Kartika T, Paquin AR, Liederbauer E, Zheng TJ, Lane L, Thein K, Shatzel JJ. Thrombotic events in patients using cyclin dependent kinase 4/6 inhibitors, analysis of existing ambulatory risk assessment models and the potential influences of tumor specific risk factors. Curr Probl Cancer 2022;:100832. [PMID: 35034766 DOI: 10.1016/j.currproblcancer.2021.100832] [Reference Citation Analysis]
4 Leiva O, AbdelHameid D, Connors JM, Cannon CP, Bhatt DL. Common Pathophysiology in Cancer, Atrial Fibrillation, Atherosclerosis, and Thrombosis: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncol 2021;3:619-34. [PMID: 34988471 DOI: 10.1016/j.jaccao.2021.08.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
5 Chang F, Zhang H, Chen C, Ke Z, Zhao M, Fan X, Zhang Y. Concomitant genetic alterations are associated with plasma D-dimer level in patients with non-small cell lung cancer. Future Oncol 2021. [PMID: 34789015 DOI: 10.2217/fon-2021-0455] [Reference Citation Analysis]
6 Di W, Xu H, Xue T, Ling C. Advances in the Prediction and Risk Assessment of Lung Cancer-Associated Venous Thromboembolism. Cancer Manag Res 2021;13:8317-27. [PMID: 34764694 DOI: 10.2147/CMAR.S328918] [Reference Citation Analysis]
7 Páramo JA, Marcos-Jubilar M, Lecumberri R. Impact of the mutation profile on thrombotic risk in cancer patients. Rev Clin Esp (Barc) 2021:S2254-8874(21)00148-X. [PMID: 34548256 DOI: 10.1016/j.rceng.2021.04.008] [Reference Citation Analysis]
8 Leiva O, Baker O, Jenkins A, Brunner AM, Al-Samkari H, Leaf RK, Rosovsky RP, Fathi AT, Weitzman J, Bornikova L, Nardi V, Hobbs GS. Association of Thrombosis With Hypereosinophilic Syndrome in Patients With Genetic Alterations. JAMA Netw Open 2021;4:e2119812. [PMID: 34357393 DOI: 10.1001/jamanetworkopen.2021.19812] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Zhu VW, Zhao JJ, Gao Y, Syn NL, Zhang SS, Ou SI, Bauer KA, Nagasaka M. Thromboembolism in ALK+ and ROS1+ NSCLC patients: A systematic review and meta-analysis. Lung Cancer 2021;157:147-55. [PMID: 34049720 DOI: 10.1016/j.lungcan.2021.05.019] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Qian X, Fu M, Zheng J, Zhou J, Zhou J. Driver Genes Associated With the Incidence of Venous Thromboembolism in Patients With Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. Front Oncol 2021;11:680191. [PMID: 33996610 DOI: 10.3389/fonc.2021.680191] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
11 Ferroni P, Guadagni F, Roselli M. Risk Prediction and New Prophylaxis Strategies for Thromboembolism in Cancer. Cancers (Basel) 2021;13:1556. [PMID: 33805252 DOI: 10.3390/cancers13071556] [Reference Citation Analysis]
12 West MT, Smith CE, Kaempf A, Kohs TCL, Amirsoltani R, Ribkoff J, Choung JL, Palumbo A, Mitri Z, Shatzel JJ. CDK 4/6 inhibitors are associated with a high incidence of thrombotic events in women with breast cancer in real-world practice. Eur J Haematol 2021;106:634-42. [PMID: 33527479 DOI: 10.1111/ejh.13590] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
13 Roopkumar J, Poudel SK, Gervaso L, Reddy CA, Velcheti V, Pennell NA, McCrae KR, Khorana AA. Risk of thromboembolism in patients with ALK- and EGFR-mutant lung cancer: A cohort study. J Thromb Haemost 2021;19:822-9. [PMID: 33314597 DOI: 10.1111/jth.15215] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
14 Frere C, Connors JM, Farge D. Management of Cancer-Associated Thrombosis: An Evolving Area. Cancers (Basel) 2020;12:E2999. [PMID: 33081109 DOI: 10.3390/cancers12102999] [Reference Citation Analysis]